Top-News
Zurück
Sophiris Bio - Reboundkanditat
Beiträge:
99
Zugriffe: 30.617 / Heute: 10
Zugriffe: 30.617 / Heute: 10
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers LevDAX Daily Swap UCITS ETF 1C
Perf. 12M: +69,05%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +49,27%
Xtrackers Harvest MSCI China Tech 100 UCITS ETF 1C
Perf. 12M: +45,56%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +44,73%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +44,65%
ihr das mit dem Produkt aus der Phase 3 könnte dort die Zulassung kommen nach dem fda Antrag.....
und wann wir dieser Antrag gestellt....
und wann wir dieser Antrag gestellt....
schon länger auf Watch.
Wird 2017 in mein Depot wandern.
Wird 2017 in mein Depot wandern.
Gelöschter Beitrag.
Einblenden
»
#57
Anzeige: Breaking News!
Setup für DOGE & LTC Mining läuft an – und diese Aktie steht in der ersten Reihe
dann lockt bei positiver News mit der aktuellen MK ein Tenbagger!
Drug Development/Clinical Research
BPH: The company successfully completed a Phase 3 clinical trial for the treatment of the symptoms of BPH. A single treatment with PRX302 (Topsalysin) demonstrated a statistically significant improvement in BPH symptoms over a 12-month period. The drug is designed to be as efficacious as pharmaceuticals, less invasive than surgical intervention, and without the sexual side effects seen with existing treatments.
The company already has a license agreement with Japan for commercialization of Topsalysin.
BPH is a $5 billion market with more than four million patients treated each year in the U.S. alone. The potential market for prostate cancer exceeds $1 billion.
The company is just one trial away from submitting an FDA application and can request the FDA to fast-track their application.
Drug Development/Clinical Research
BPH: The company successfully completed a Phase 3 clinical trial for the treatment of the symptoms of BPH. A single treatment with PRX302 (Topsalysin) demonstrated a statistically significant improvement in BPH symptoms over a 12-month period. The drug is designed to be as efficacious as pharmaceuticals, less invasive than surgical intervention, and without the sexual side effects seen with existing treatments.
The company already has a license agreement with Japan for commercialization of Topsalysin.
BPH is a $5 billion market with more than four million patients treated each year in the U.S. alone. The potential market for prostate cancer exceeds $1 billion.
The company is just one trial away from submitting an FDA application and can request the FDA to fast-track their application.
Es gibt keine neuen Beiträge.
Ich:
|
